Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Executive Summary
Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.
You may also be interested in...
Rx Drug Promotion: Potential Enforcement Worries
Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.
Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement
Settlement with US government also includes $225m payment to resolve criminal and civil cases related to illegal marketing of the sublingual fentanyl spray Subsys.
Opioid Makers May Have To Pay For Prevention Costs Of 'Man-Made Plague,' Judge Suggests
Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.